Press coverage about C R Bard (NYSE:BCR) has trended positive this week, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. C R Bard earned a daily sentiment score of 0.32 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 45.3317861877906 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
A number of research analysts have weighed in on the stock. Cowen reissued a “hold” rating and set a $317.00 target price on shares of C R Bard in a research note on Friday, November 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of C R Bard in a research note on Thursday, October 26th. ValuEngine lowered shares of C R Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Barclays upped their price objective on shares of C R Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a report on Monday, November 6th. Finally, Zacks Investment Research upgraded shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price objective on the stock in a report on Tuesday, December 26th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $320.83.
Shares of C R Bard (NYSE:BCR) opened at $331.24 on Tuesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37. C R Bard has a 52-week low of $222.42 and a 52-week high of $337.73. The company has a market capitalization of $24,140.00, a P/E ratio of 43.64, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52.
TRADEMARK VIOLATION WARNING: “C R Bard (NYSE:BCR) Earns Media Impact Rating of 0.32” was published by BBNS and is owned by of BBNS. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://baseballnewssource.com/markets/c-r-bard-bcr-earns-daily-media-impact-rating-of-0-32/1810476.html.
C R Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.